ReviewFrontiers in medicine2026
Current perspectives and updates on transfusion strategies in critically ill anemic patients.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia is a frequently encountered condition in critically ill patients, and red blood cell transfusion serves as a critical therapeutic intervention aimed at restoring hemoglobin levels and improving tissue oxygenation. However, the optimal threshold for transfusion remains a subject of controversy, particularly regarding the comparison between restrictive (Hb 7-9 g/dL) and liberal (Hb > 9 g/dL) strategies. However, we should also consider a third option. This method focuses on the individual patient. Doctors adjust care based on the patient's specific symptoms and other health problems. The selection of the appropriate strategy is contingent upon specific clinical conditions, such as sepsis, acute coronary syndrome, or neurological injury. Current evidence and clinical guidelines predominantly favor a restrictive transfusion in hemodynamically stable patients, whereas a liberal strategy may benefit those with underlying cardiovascular disease. This review synthesizes recent trial data and guideline recommendations to facilitate evidence-based and individualized transfusion decision-making in the ICU, aiming to optimize the balance between risks and benefits across diverse critical care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.